Section Arrow
ENTA.NASDAQ
- Enanta Pharmaceuticals
Quotes are at least 15-min delayed:2026/06/02 12:11 EDT
Regular Hours
Last
 12.02
-0.65 (-5.13%)
Day High 
12.6 
Prev. Close
12.67 
1-M High
15.93 
Volume 
68.12K 
Bid
11.99
Ask
12.01
Day Low
11.98 
Open
12.51 
1-M Low
12.5 
Market Cap 
368.42M 
Currency 美元 
P/E -- 
%Yield -- 
10-SMA 13.44 
20-SMA 14.02 
50-SMA 13.64 
52-W High 17.15 
52-W Low 6.435 
Exchange NASDAQ 
Valuation Estimation
EPS (Current/Estimated)
-2.60/-2.53
Enterprise Value
423.18M
Balance Sheet
Book Value Per Share
4.01
Cash Flow
Cash Flow Yield
--
Income Statement
Total Revenue
41.71M
Operating Revenue Per Share
2.77
Industry Comparison
Code Name   Last Change Change (%) P/E P/E Range
EVGNEvogene Ltd.0.6127-0.0703-10.29%-- 
ADTXAditxt Inc.0.113------ 
FULCFulcrum Therapeutics2.97-3.45-53.74%-- 
AIMAIM ImmunoTech Inc.0.767-0.1316-14.65%-- 
ABVXAbivax SA71.595-58.095-44.80%-- 
Industry overview quotes are at least 15 minutes delayed (Except Overnight Trading Session)
Business Description
Enanta Pharmaceuticals Inc is a biotechnology company that uses a chemistry-based drug discovery approach to develop small-molecule candidates for virology and immunology applications. It focuses on Virology and Immunology. Its active development programs in virology are focused on respiratory syncytial virus, or RSV, and SARS-CoV-2, and Hepatitis B virus. In immunology, the company is engaged in designing and developing potent and selective, oral small molecule inhibitors for the treatment of type 2 inflammatory disease. The company has collaborated with AbbVie, which markets its protease inhibitor paritaprevir, with additional inhibitors in development. The company generates the majority revenue in the form of royalty revenue.
Information provided by: etnet
Terms and Conditions
Bank of China (Hong Kong) Limited
Disclaimer:
This information is provided by ET Net Limited ("ET Net") and/or its third party information providers (the "Sources") and is strictly for reference only. It is not intended to provide any financial or professional advice and any person should not rely upon the same as such. You should obtain relevant and specific professional advice before making any investment decision. Before making an investment decision, you should consider, with the assistance of your professional securities adviser, whether the information is appropriate in light of your particular investment needs, objectives and financial circumstances. ET Net and the Sources endeavor to ensure the accuracy and reliability of the information provided. Notwithstanding the aforesaid, ET Net, the Sources and Bank of China (Hong Kong) Limited do not guarantee or make any representation, warranty or undertaking as to the accuracy, reliability, completeness or timeliness of this information, and accept no responsibility or liability whatsoever (whether in tort or contract or otherwise) for any loss or damage howsoever arising from or in reliance upon the whole or any part of such information.